Psoriasis News and Research RSS Feed - Psoriasis News and Research

Psoriasis is a chronic, immune-mediated disease that results from the overproduction of skin cells, resulting in their accumulation on the surface of the skin, which causes red, scaly plaques that may itch and bleed. It is estimated that approximately 7.5 million Americans and nearly 3 percent of the world's population are living with psoriasis and nearly one-quarter of those people have cases that are considered moderate to severe.
FDA approves new biosimilar for multiple inflammatory diseases

FDA approves new biosimilar for multiple inflammatory diseases

The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. [More]
Skin phenotype of pediatric eczema opens door for personalized treatment of AD in infants

Skin phenotype of pediatric eczema opens door for personalized treatment of AD in infants

Researchers for the first time have identified the skin phenotype of pediatric eczema or atopic dermatitis (AD) in infants, opening the door for personalized treatment approaches for young children with eczema. [More]
TSRI scientists shed light on molecular workings of MS drug

TSRI scientists shed light on molecular workings of MS drug

A study by scientists at The Scripps Research Institute has helped to de-mystify the molecular workings of the multiple sclerosis (MS) drug Tecfidera. The drug is the most widely prescribed pill-based therapy for MS, but its biological mechanism remains mysterious. [More]
Food intolerance testing: an interview with Dr Gill Hart

Food intolerance testing: an interview with Dr Gill Hart

Food intolerances are caused by adverse reactions to food or drink ingredients in your body. These are very different to food allergies. It is estimated that up to forty-five percent of the population suffers from food intolerances. [More]
Could a light-listening photonics device detect skin disease? An interview with Prof. Vasilis Ntziachristos

Could a light-listening photonics device detect skin disease? An interview with Prof. Vasilis Ntziachristos

Detection of malignant skin alterations is currently aided by optical microscopes such as dermoscopes or optical microscopes. While the latter offers high resolution, it comes with a major disadvantage, just like any other purely microscopic method: it only provides a partial view of the skin due to the low penetration depth. [More]
Can-Fite BioPharma reports financial results, provides update on drug development programs

Can-Fite BioPharma reports financial results, provides update on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2016 and updates on its drug development programs. [More]
Penn State dermatologist clarifies common myths about psoriasis

Penn State dermatologist clarifies common myths about psoriasis

Psoriasis is a much-misunderstood disease, often kept under wraps by sufferers who want to hide their skin lesions. [More]
Prevalence of coronary calcification similar between patients with psoriasis and type 2 diabetes

Prevalence of coronary calcification similar between patients with psoriasis and type 2 diabetes

Assessing coronary artery calcium (CAC) is a measure of the severity of atherosclerosis (clogged arteries) and a cornerstone for screening for risk of future cardiac events. The inflammatory skin condition psoriasis has been associated with increased risk of cardiovascular disease. [More]
Research finding opens door to new treatment options for inflammatory rheumatism

Research finding opens door to new treatment options for inflammatory rheumatism

Enthesitis, inflammation of tendons where they attach to the bone, is a common medical problem which underlies various forms of inflammatory rheumatism. [More]

Combination of biologic and phototherapy treatment appears to be safe, effective in treating psoriasis

The review, entitled "Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability," was carried out by a group of researchers in the USA. [More]
Generic biologic drugs appear to be as effective as brand-name versions

Generic biologic drugs appear to be as effective as brand-name versions

Generic forms of a biologic drug used to treat rheumatoid arthritis, inflammatory bowel disease and psoriasis appear to be as safe and effective as their brand-name counterparts, a new Johns Hopkins Bloomberg School of Public Health analysis suggests. [More]
Psoriasis treatments may help improve cardiovascular symptoms by reducing skin inflammation

Psoriasis treatments may help improve cardiovascular symptoms by reducing skin inflammation

Approximately 7.5 million people in the United States have psoriasis, and the impact of this disease goes far beyond its visible effects on the skin. [More]
New report reveals prescription medication costs may increase up to 13% in 2016

New report reveals prescription medication costs may increase up to 13% in 2016

Prescription medication costs are expected to rise at least 11 percent, and possibly up to 13 percent, in 2016, according to a new report on national trends and projections in prescription drug expenditures. [More]
New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product

New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product

Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met. [More]
Study demonstrates role of leukocyte activation receptor CD69 in development of psoriasis

Study demonstrates role of leukocyte activation receptor CD69 in development of psoriasis

Scientists at the Centro de Investigaciones Cardiovasculares Carlos III have defined the key role of an immune-system receptor in the development of psoriasis, suggesting that it could serve as a therapeutic target for the control of this disease. [More]
Global survey reveals 84% of psoriasis patients suffer discrimination, humiliation

Global survey reveals 84% of psoriasis patients suffer discrimination, humiliation

Novartis today released new results from the largest global survey to date of people with psoriasis. [More]
New PsA-comorbidity index may help identify patients at risk of hospitalisation and premature death

New PsA-comorbidity index may help identify patients at risk of hospitalisation and premature death

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that a newly developed method of evaluating the impact of different comorbidities in patients with Psoriatic Arthritis (PsA) can be used to prospectively identify those PsA patients at greater risk of hospitalisation and premature death. [More]
New drug ixekizumab helps clear severe psoriasis symptoms

New drug ixekizumab helps clear severe psoriasis symptoms

About 80 percent of patients with moderate to severe psoriasis saw their disease completely or almost completely cleared with a new drug called ixekizumab, according to three large, long-term clinical trials led by Northwestern Medicine. [More]
B lymphocytes can influence psoriasis by regulating cytokine IL-10

B lymphocytes can influence psoriasis by regulating cytokine IL-10

"A pathological and very complex autoimmune reaction of the skin": This is the definition doctors and scientists use to describe psoriasis, a disease that affects one to three percent of the population. [More]
Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

A significant proportion of lung cancer patients also have autoimmune disease, which may make them unsuitable for increasingly popular immunotherapy treatments, a team of researchers at UT Southwestern Medical Center's Harold C. Simmons Comprehensive Cancer Center has found. [More]
Advertisement